The coronavirus disease-2019 (COVID-19) pandemic continues to be a cause of unprecedented global morbidity and mortality. Whilst COVID-19 vaccination has emerged as the only tangible solution to reducing poor clinical outcomes, vaccine hesitancy continues to be an obstacle to achieving high levels of vaccine uptake. This represents particular risk to patients with autoimmune diseases, a group already at increased risk of hospitalization and poor clinical outcomes related to COVID-19 infection. Whilst there is a paucity of long-term safety and efficacy data of COVID-19 vaccination in patients with autoimmune diseases, the current evidence strongly suggests that the benefits of vaccination outweigh the risks of adverse effects and disease flares. Herein, we report the protocol of the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study, an ongoing international collaborative study involving 29 countries and over 110 investigators.
Covid-19 vaccination in autoimmune disease (COVAD) survey protocol / Sen, Parikshit; Gupta, Latika; Lilleker, James B; Aggarwal, Vishwesh; Kardes, Sinan; Milchert, Marcin; Gheita, Tamer; Salim, Babur; Velikova, Tsvetelina; Gracia-Ramos, Abraham Edgar; Parodis, Ioannis; O'Callaghan, Albert Selva; Nikiphorou, Elena; Tan, Ai Lyn; Cavagna, Lorenzo; Saavedra, Miguel A; Shinjo, Samuel Katsuyuki; Ziade, Nelly; Knitza, Johannes; Kuwana, Masataka; Cagnotto, Giovanni; Nune, Arvind; Distler, Oliver; Chinoy, Hector; Aggarwal, Vikas; Aggarwal, Rohit; Barman, Bhupenai; Singh, Yogesh Preetaj; Ranjan, Rajivak; Jain, Avinashal; Pandya, Sapan C. am; Malaviya A. N., An; Pilania, Rakesh Kumarao; Sharma, Amanap; Manoj, M. Maneshaq; Gupta, Vikasar; Kavadichanda, Chengappa G. as; Patro, Pradeepta Sekharat; Ajmani, Sajalau; Phatak, Sanatav; Goswami, Rudra Prosadaw; Chowdhury, Abhra Chandraax; Mathew, Ashish Jacobay; Shenoy, Padnamabhaaz; Asranna, Ajayba; Bommakanti, Keerthi Talaribb; Shukla, Anujbc; Naveen R., Bd; Cansu, ; Döndü, Üsküdarbe; Bf, ; Pauling, John D. bg; Wincup, Chrisbh; Chatterjee, Tulikabi; Kim, Minchulbj; Giannini, Margheritabk; Del Papa, Nicolettabl; Sambataro, Gianlucabm; Fabiola, Atzenibn; Govoni, Marcellobo; Bp, ; Parisi, Simonebq; Bocci, Elena Bartolonibr; Sebastiani, Gian Domenicobs; Fusaro, Enricobt; Sebastiani, Marcobu; Quartuccio, Lucabv; Franceschini, Francobw; Sainaghi, Pier Paolobx; Orsolini, Giovanniby; De Angelis, Rossella; Danielli, Maria Giovanna; Traboco, Lisa S. ca; Wibowo, Suryo Anggoro Kusumocb; Serrano, ; Jorge, Rojascc; Cd, ; La Torre, Ignacio García-Dece; Tehozol, Erick Adrian Zamoracf; Loarce-Martos, Jesúscg; Prieto-González, Sergioch; Gil-Vila, Albertci; Aranega, Raquelcj; Nakashima, Ranck; Sato, Shinjicl; Kimura, Naokicm; Cn, ; Kaneko, Yukoco; Tomaras, Stylianoscp; Gromova, Margarita Aleksandrovnacq; Aharonov, Orcr. - In: RHEUMATOLOGY INTERNATIONAL. - ISSN 1437-160X. - 42:1(2022), pp. 23-29. [10.1007/s00296-021-05046-4]
Covid-19 vaccination in autoimmune disease (COVAD) survey protocol
De Angelis, Rossella;
2022-01-01
Abstract
The coronavirus disease-2019 (COVID-19) pandemic continues to be a cause of unprecedented global morbidity and mortality. Whilst COVID-19 vaccination has emerged as the only tangible solution to reducing poor clinical outcomes, vaccine hesitancy continues to be an obstacle to achieving high levels of vaccine uptake. This represents particular risk to patients with autoimmune diseases, a group already at increased risk of hospitalization and poor clinical outcomes related to COVID-19 infection. Whilst there is a paucity of long-term safety and efficacy data of COVID-19 vaccination in patients with autoimmune diseases, the current evidence strongly suggests that the benefits of vaccination outweigh the risks of adverse effects and disease flares. Herein, we report the protocol of the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study, an ongoing international collaborative study involving 29 countries and over 110 investigators.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
